Virosomes

Novel Immunologic Adjuvants

Volumn , Issue , 2011, Pages 43-53

  Moser, Christian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877256253     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.11.8     Document Type: Chapter

References (24)

1. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787-796 (2010).
2. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 40(1), 60-65 (2006).
3. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol. Chem. 389(5), 521-536 (2008).
4. Amacker M, Moese S, Kammer AR, Helenius A, Zurbriggen R. Influenza virosomes as delivery systems for antigens. In: Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids, and Vaccines. Jorgensen L, Nielsen HM (Eds). John Wiley & Sons, NJ, USA 377-393 (2009).
5. Kammer AR, Amacker M, Rasi S et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine 25(41), 7065-7074 (2007).
6. Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev. Vaccines 10(4), 437-446 (2011).
7. Amacker M, Engler O, Kammer AR et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol. 17(6), 695-704 (2005).
8. Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G, Daubenberger CA. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a Phase I subunit malaria vaccine trial. Clin. Immunol. 127(2), 188-197 (2008).
9. Ribeiro CMS, Schijns VEJC: Immunology of vaccine adjuvants. In: Vaccine Adjuvants. Davies G (Eds). Springer, Berlin, Germany 1-14 (2010)
10. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 98(4), 1278-1316 (2009).
11. De Gregorio E, D'Oro U, Wack A: Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol. 21(3), 339-345 (2009).
12. Angel J, Chaperot L, Molens JP et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 25(19), 3913-3921 (2007).
13. Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20(17-18), 2287-2295 (2002).
14. + T cell activation. Vaccine 22, 714-723 (2004).
15. Van der Wielen M, Vertruyen A, Froesner G et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Pediatr. Infect. Dis. J. 26(8), 705-710 (2007).
16. Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert. Rev. Vaccines 7(8), 1141-1150 (2008).
17. Herzog C, Hartmann K, Kunzi V et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 27(33), 4381-4387 (2009).
18. Genton B, Pluschke G, Degen L et al. A randomized placebo-controlled Phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE 2(10), e1018 (2007).
19. th Annual Meeting of the American Society of Tropical Medicine and Hygiene Atlanta, GA, USA, 3-7 November 2010.
20. Thompson FM, Porter DW, Okitsu SL et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial. PLoS ONE 3(1), e1493 (2008).
21. Wiedermann U, Wiltschke C, Jasinska J et al. A virosomal formulated HER-2/neu multi-peptide vaccine induces HER-2/neu-specific immune responses in patients with metastatic breast cancer: a Phase I study. Breast Cancer Res. Treat. 119(3), 673-683 (2010).
22. Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 GP41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 34(2), 269-280 (2011).
23. Mymetics www.mymetics.com
24. Pevion Biotech AG www.pevion.com